Laser Therapy for Spinal Metastases
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new laser therapy, Spinal Laser Interstitial Therapy, for tumors that have spread to the spine. Researchers aim to determine if this laser treatment can control tumors as effectively as traditional surgery. Individuals with confirmed spinal tumors between the T2 and T12 spine areas, who require spinal radiation or a relief procedure and have a normal neurologic exam, might be suitable candidates. The goal is to identify a treatment option that is both effective and safe for those with these specific spinal tumors. As an unphased trial, this study provides patients the chance to explore innovative treatments that could enhance their quality of life.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that spinal laser interstitial therapy is safe for treating metastatic spinal tumors?
Research has shown that spinal laser interstitial therapy (sLITT) safely treats spinal tumors. Studies have found that sLITT eases pressure on the spinal cord with few side effects. One study demonstrated its effectiveness in controlling tumor growth, particularly in the upper and middle back. This treatment is minimally invasive, involving less cutting and generally being easier on the body. Previous reports confirm that patients tolerate sLITT well, making it a promising option for those with spinal metastases.12345
Why are researchers excited about this trial?
Spinal Laser Interstitial Thermal Therapy (sLITT) is unique because it uses laser technology to precisely target and treat spinal metastases. Unlike traditional treatments like surgery or radiation, which can affect large areas and have longer recovery times, sLITT aims to minimize damage to surrounding healthy tissues and potentially shorten recovery periods. Researchers are excited about this treatment due to its minimally invasive nature and its potential to provide more effective pain relief and better quality of life for patients dealing with spinal metastases.
What evidence suggests that spinal laser interstitial therapy is effective for metastatic spinal tumors?
Research has shown that spinal laser interstitial thermal therapy (sLITT), which participants in this trial will receive, effectively controls tumors in the spine. Studies have demonstrated that sLITT helps manage epidural spinal cord compression, a condition that occurs when cancer spreads to the spine. In a study of 120 cases, sLITT provided good tumor control while remaining safe. A review of multiple studies found that sLITT effectively relieves pressure on the spinal cord with few complications. These findings suggest that sLITT can be a safe and effective option for treating cancer that has spread to the spine.12346
Are You a Good Fit for This Trial?
This trial is for individuals with confirmed spinal tumors in the T2-T12 spine segments who need radiosurgery or palliative care. They must have normal neurological function (Frankel grade E) at the start. Specific details on who cannot join are not provided.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients undergo spinal laser interstitial thermal therapy using the Visualase Thermal Therapy System
Follow-up
Participants are monitored for local tumor control and neurologic function post-operatively
What Are the Treatments Tested in This Trial?
Interventions
- Spinal Laser Interstitial Therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dartmouth-Hitchcock Medical Center
Lead Sponsor